0000950170-24-040615.txt : 20240402 0000950170-24-040615.hdr.sgml : 20240402 20240402205022 ACCESSION NUMBER: 0000950170-24-040615 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240329 FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nguyen Nate CENTRAL INDEX KEY: 0002016255 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 24816623 MAIL ADDRESS: STREET 1: C/O CULLINAN ONCOLOGY, INC. STREET 2: ONE MAIN STREET, SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Oncology, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813867811 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 1350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Management, Inc. DATE OF NAME CHANGE: 20210107 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 3 1 ownership.xml 3 X0206 3 2024-03-29 0 0001789972 Cullinan Oncology, Inc. CGEM 0002016255 Nguyen Nate C/O CULLINAN ONCOLOGY, INC. ONE MAIN STREET, SUITE 1350 CAMBRIDGE MA 02142 false true false false Interim PAO and PFO Common Stock 6250 D Common Stock 13375 D Common Stock 13375 D Stock Option (Right to Buy) 48.39 2031-02-28 Common Stock 75000 D Stock Option (Right to Buy) 13.60 2032-02-11 Common Stock 62500 D Stock Option (Right to Buy) 11.34 2033-02-17 Common Stock 26750 D Stock Option (Right to Buy) 17.54 2034-02-22 Common Stock 26750 D The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of February 11, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of February 17, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. The shares underlying the restricted stock unit vest over four years until the fourth anniversary of February 22, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares vested on January 25, 2022, and the remaining shares vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of February 11, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of February 17, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of February 22, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Exhibit 24 - Power of Attorney /s/ Jacquelyn Sumer, Attorney-in-Fact 2024-04-02 EX-24 2 cgem-ex24.htm EX-24 EX-24

 

POWER OF ATTORNEY

 

The undersigned hereby constitutes and appoints Jacquelyn Sumer, signing singly, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned’s capacity as officer and/or director of Cullinan Oncology, Inc., a Delaware corporation (the “Company”), from time to time the following U.S. Securities and Exchange Commission (the “SEC”) forms: (i) Form ID, including any attached documents (such as Update Passphrase Authentication), to effect the assignment of codes to the undersigned to be used in the transmission of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities, including any attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules thereunder, including any attached documents; and (v) amendments of each thereof, in accordance with the Exchange Act, and the rules thereunder, including any attached documents;

 

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 or any amendment(s) thereto and timely file such form(s) with the SEC and any securities exchange, national association or similar authority; and

 

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act. The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned’s capacity as an officer and/or director of the Company. This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an employee of the Company.

 

[Signature Page Follows]

 

 

 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of April 1, 2024.

 

 

 

/s/ Nate Nguyen

Signature

 

Nate Nguyen

Print Name